Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nezulcitinib in COVID-19 Associated Acute Lung Injury
NCT04402866Phase 2Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jun 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of nezulcitinib in coronavirus disease 2019 (COVID-19), acute lung injury (ALI), sponsored by Theravance Biopharma, Inc.. Started Jun 2020; status: completed.
02
Drugs
nezulcitinib
03
Conditions
coronavirus disease 2019 (COVID-19)acute lung injury (ALI)
Beyond the preview
Go deeper on NCT04402866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402866.